{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-012993","form_type":"8-K","ticker":"SION","cik":"0002036042","company_name":"Sionna Therapeutics, Inc.","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.084783+00:00","generated_at":"2026-05-15T22:51:42.743786+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sionna Therapeutics Q4 2025 net loss $20.4M; cash $310.3M funds into 2028","bullets":["Net loss $20.4M (Q4) and $75.3M (FY 2025) vs $15.8M and $61.7M in 2024.","Cash and equivalents $310.3M as of Dec 31, 2025; expected to fund operations into 2028.","Phase 2a PreciSION CF trial of SION-719 on track; topline data expected mid-2026.","Phase 1 dual combo trial of SION-451 with SION-2222/SION-109 on track; data mid-2026.","R&D expenses $15.2M (Q4) and $60.3M (FY); G&A expenses $8.4M (Q4) and $28.7M (FY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-012993","json":"https://secwatch.observer/filing/0001628280-26-012993.json","markdown":"https://secwatch.observer/filing/0001628280-26-012993.md","text":"https://secwatch.observer/filing/0001628280-26-012993.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2036042/000162828026012993/0001628280-26-012993-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2036042/000162828026012993/sion-20260302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:51:42.743786+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}